Antibodies for Cancer Therapy Conference 2014

Antibodies for Cancer Therapy

Exploiting Successful Strategies

Part of the Tenth Annual PEGS: the essential protein engineering summit

May 5-6, 2014| Seaport World Trade Center | Boston, MA

This conference will focus on the current status of therapeutic antibodies and on the outlook for the future. This year’s agenda will highlight diverse topics such as identifying and validating novel targets, optimizing drug-like properties, increasing tumor penetration, employing novel constructs, and regulating novel therapeutic antibodies. Additionally, emphasis will be placed on learning from molecules in clinical development. We will review the vibrant community of therapeutic antibodies and discover the latest trends for future best-in-class drugs.

Topics include:

• Investigating hot targets in cancer antibodies including CTLA4, PD1 and CD47

• Contrasting immunotherapy approaches

• Discovering and validating novel targets for antibody engineering

• Reviewing the recent successes

• Targeting cancer initiating cells with monoclonal antibodies

• Factoring the tumor microenvironment into immunotherapy

• Exploring mechanisms of immunomodulatory drugs

• Reviewing strategies of industry-academic collaborations in antibody engineering

• Understanding impact of technology on clinical efficacy

• Improved glycosylation of bispecific antibodies

• New technologies for making humanized antibodies